Current Report Filing (8-k)
March 20 2017 - 7:38AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): March 20, 2017
NEKTAR THERAPEUTICS
(Exact Name of Registrant as Specified
in Charter)
Delaware
|
|
0-24006
|
|
94-3134940
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
455 Mission Bay Boulevard South
San Francisco, California 94158
(Address of Principal Executive Offices
and Zip Code)
Registrant’s telephone number, including
area code: (415) 482-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (
see
General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
On March 20, 2017, Nektar Therapeutics,
a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing the results
from the SUMMIT-07 Phase 3 efficacy study for NKTR-181 in the treatment of patients with moderate to severe chronic low back pain.
A copy of the Press Release reporting results from the Phase 3 Study is furnished herewith as Exhibit 99.1.
In the Press Release, Nektar announced that
it would hold a Webcast conference call on March 20, 2017 at 5:45 a.m. (Pacific Time)/8:45 a.m. (Eastern Time) on March 20, 2017
to review the results from the Phase 3 SUMMIT-07 study. This conference call is accessible through a link that is posted on the
home page and Investor section of the Nektar website: http://www.nektar.com.
The information in
this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not
be incorporated by reference into any filing with the Securities and Exchange Commission made by Nektar Therapeutics, whether made
before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01
|
|
Financial Statements and Exhibits.
|
Exhibit
Number
|
|
Description
|
|
|
|
99.1
|
|
Press Release titled “NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain” issued by Nektar Therapeutics on March 20, 2017.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
NEKTAR THERAPEUTICS
|
|
|
|
March 20, 2017
|
By:
|
/s/ Mark A. Wilson
|
|
|
Mark A. Wilson
|
|
|
General Counsel and Secretary
|
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release titled “NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain” issued by Nektar Therapeutics on March 20, 2017.
|
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Apr 2023 to Apr 2024